Source: Moffitt Cancer Center, May 2025
Tumor-infiltrating lymphocyte (TIL) therapy is a type of cellular immunotherapy in which a patient’s own cells are used to destroy tumor-based cancers.
Last year, the U.S. Food and Drug Administration (FDA) approved TIL therapy as another option to treat advanced melanoma.
During the treatment, immune cells are extracted from the patient’s tumor, multiplied in the lab and then infused back into the patient where they seek out and attack cancer cells.